1. Home
  2. CNTN vs VTVT Comparison

CNTN vs VTVT Comparison

Compare CNTN & VTVT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CNTN

Canton Strategic Holdings Inc. Common Stock

N/A

Current Price

$2.03

Market Cap

185.3M

Sector

Health Care

ML Signal

N/A

Logo vTv Therapeutics Inc.

VTVT

vTv Therapeutics Inc.

HOLD

Current Price

$31.02

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CNTN
VTVT
Founded
2017
2015
Country
United States
United States
Employees
12
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
185.3M
148.7M
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
CNTN
VTVT
Price
$2.03
$31.02
Analyst Decision
Strong Buy
Analyst Count
0
5
Target Price
N/A
$53.00
AVG Volume (30 Days)
677.0K
74.4K
Earning Date
05-13-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$14.00
52 Week High
$5.27
$44.00

Technical Indicators

Market Signals
Indicator
CNTN
VTVT
Relative Strength Index (RSI) 37.11 39.64
Support Level N/A $29.85
Resistance Level $3.80 $33.11
Average True Range (ATR) 0.17 1.89
MACD -0.02 -0.28
Stochastic Oscillator 21.74 13.94

Price Performance

Historical Comparison
CNTN
VTVT

About CNTN Canton Strategic Holdings Inc. Common Stock

Canton Strategic Holdings Inc is engaged in activities related to Canton Network, including the use of Canton Coin, to support blockchain-based infrastructure and the digitization of financial market processes. The company also operates a validator node on the Canton Network to facilitate transaction validation and network operations. It also operates a clinical-stage biotech research and development arm. Its flagship clinical asset, GV104, is being developed for a specific indication for respiratory and/or nervous system depression in military personnel and chemical incident responders. The expanded pipeline includes other indications for GV104 and GV023, an approach to autoimmune diseases as well as an early-stage multispecific biologic platform.

About VTVT vTv Therapeutics Inc.

vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Share on Social Networks: